US biopharmaceutical company Pfizer Inc (NYSE:PFE) and its German partner BioNTech SE (Nasdaq:BNTX) said on Monday that a third shot of their COVID-19 vaccine has been shown to be effective in young children.
In a Phase 2/3 trial which took place at a time when Omicron was the predominant variant, vaccine efficacy was 80.3% in children aged 6 months to under 5 years of age.
A total of 1,678 children took part in the trial, receiving a third shot of the low-dose formulation at least two months after their second shot.
Pfizer and BioNTech plan to submit the new data to the US Food and Drug Administration (FDA) this week, with submissions to the European Medicines Agency (EMA) and other regulators to follow.
Philips launches integrated IntraSight Plus platform to enhance coronary intervention efficiency
Hope Medicine reports first patient dosed in Phase III trial of HMI-115
Orsini chosen as single-source specialty pharmacy partner for Glaukos' Epioxa
GE HealthCare's Photonova Spectra gains FDA clearance
Futura Medical reports positive home user test results for Eroxon and Intense variant
GSK secures Japan Orphan Drug status for lung cancer ADC
Belief BioMed enters exclusive partnership with Grand Life Sciences for haemophilia A treatment
Glaukos launches Epioxa to advance incision-free treatment for keratoconus
Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease
Sentynl Therapeutics and PRG S&T enter licensing agreement for potential HGPS treatment